A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD)
about
Evaluation of traditional medicines for neurodegenerative diseases using Drosophila modelsThe Solution Structure and Dynamics of Full-length Human Cerebral Dopamine Neurotrophic Factor and Its Neuroprotective Role against α-Synuclein Oligomers.Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathiesNovel therapeutic approaches in multiple system atrophyHigh Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model.The emerging role of nutrition in Parkinson's disease.Animal models of Parkinson's disease: a gateway to therapeutics?Exercise and Nutritional Benefits in PD: Rodent Models and Clinical Settings.Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.Animal models of α-synucleinopathy for Parkinson disease drug development.Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.Self-Assembled Cyclic d,l-α-Peptides as Generic Conformational Inhibitors of the α-Synuclein Aggregation and Toxicity: In Vitro and Mechanistic Studies.Mini-review on initiatives to interfere with the propagation and clearance of alpha-synuclein in Parkinson's disease.A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.Interference of α-Synuclein Uptake by Monomeric β-Amyloid1-40 and Potential Core Acting Site of the Interference.
P2860
Q27027455-8873D91B-191A-4FEA-8DA6-552BA08A4E8AQ30376382-126772A6-2F41-43F4-B4F3-63B47D6B7EE3Q33715640-DE41388C-A999-4656-9D8A-CEC08A2E4AE0Q34696470-8FB1625A-8EA4-43EE-B471-368D49284214Q35771016-F8BE8276-21DF-4317-8FFC-996D8EF140ADQ37622710-33553BF7-7D54-4C12-8E56-D7A8BE491174Q38155480-FA3DFB51-8A5A-41D6-8AFB-59B5F87ADBD6Q38686112-AB7DA8DF-D7B0-4E2B-8300-A741C18C8035Q38766966-4C860EDC-4FC7-4EFD-B821-F6424E0FD0A3Q40106906-CD35C410-F1D9-4F6C-9585-4B198571F53FQ41623081-D6C1639F-0EE1-40BD-BF8B-0A8B33FA6D14Q46500132-377E245B-2A7A-4620-9FF3-0209DC60638EQ47123483-2D9D6CDF-8911-45FA-95E6-C2E852B0DA25Q48493933-68D8DCC6-CE99-4279-BE7D-4984F0AC2E8AQ48647283-C6D14A74-0034-491B-A944-97F60842CACD
P2860
A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD)
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
A blood-brain barrier (BBB) di ...... ment of Parkinson disease (PD)
@ast
A blood-brain barrier (BBB) di ...... ment of Parkinson disease (PD)
@en
A blood-brain barrier (BBB) di ...... ment of Parkinson disease (PD)
@nl
type
label
A blood-brain barrier (BBB) di ...... ment of Parkinson disease (PD)
@ast
A blood-brain barrier (BBB) di ...... ment of Parkinson disease (PD)
@en
A blood-brain barrier (BBB) di ...... ment of Parkinson disease (PD)
@nl
prefLabel
A blood-brain barrier (BBB) di ...... ment of Parkinson disease (PD)
@ast
A blood-brain barrier (BBB) di ...... ment of Parkinson disease (PD)
@en
A blood-brain barrier (BBB) di ...... ment of Parkinson disease (PD)
@nl
P2093
P2860
P921
P356
P1476
A blood-brain barrier (BBB) di ...... ment of Parkinson disease (PD)
@en
P2093
Abigail Schiller
Christina Patrick
Daniel Segal
Ehud Gazit
Michal Levy-Sakin
Moran Frenkel-Pinter
Nirit Egoz-Matia
Ronit Shaltiel-Karyo
P2860
P304
P356
10.1074/JBC.M112.434787
P407
P577
2013-06-14T00:00:00Z